Testing HIV antibodies plus early HIV treatment for possible remission
Treatments studied
Part of Infections clinical trials.
This trial tests whether giving two powerful HIV-fighting antibodies (called broadly neutralizing monoclonal antibodies) along with starting standard HIV medications soon after infection can help control the virus without needing daily pills. If successful, it might allow people to take a 'treatment pause' while keeping their immune system healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must weigh under 253 pounds (about 115 kg).
- You must have been diagnosed with HIV recently (within a few months).
- You must not have taken any HIV medications (including prevention pills like PEP or PrEP) recently.
- You must be willing to start HIV medications (ART) and later have a monitored pause (called an analytical treatment interruption).
- You must agree to use reliable contraception to avoid pregnancy and to prevent passing HIV to partners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding an experimental vaccine can help your immune system control HIV during a temporary break from your antiretroviral therapy (ART). If you have been on ART since shortly after infection with a suppressed viral load, this trial could help you understand if a 'functional cure' is possible.
This study tests if two lab-made antibodies can keep HIV under control when people temporarily stop their daily HIV medication. Participants will pause their antiretroviral therapy (ART) for a period and be closely monitored, with the goal of potentially finding a way to take a break from daily pills.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
Hear when a new Acute HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.